Ebr Systems, INC 10-Q quarterly reports

EBR Systems, Inc. reported increased net sales for Q2 2026, but also disclosed substantial doubt about its ability to continue as a going concern, despite FDA approval of its WiSE CRT System.

EBR Systems, Inc. reported its first quarter 2026 financial results, generating $2.4 million in revenue but facing substantial doubt about its ability to continue as a going concern.

EBR Systems, Inc. reported an increased net loss for the third quarter and first nine months of 2025 despite commencing commercial sales of its FDA-approved WiSE CRT System and securing significant capital.

EBR Systems reports its WiSE CRT System received FDA approval, leading to initial commercial revenue and a significant capital raise, extending its financial runway into 2027.

EBR Systems announces FDA approval for its WiSE CRT System and reports a net loss of $10.6 million for Q1 2025.

EBR Systems, a medical device company, announced its Q3 2024 financial results, highlighting ongoing development of its WiSE CRT System and a recent capital raise.